<DOC>
	<DOC>NCT01082809</DOC>
	<brief_summary>The purpose of this study is to determine whether sunitinib as second-line treatment in advanced biliary tract carcinoma</brief_summary>
	<brief_title>Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma</brief_title>
	<detailed_description>Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: multicenter, multinational study</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1. age â‰¥ 18 2. histologically or cytologically confirmed adenocarcinoma of biliary tract 3. unresectable or metastatic 4. ECOG performance status of 0~2 5. measurable or evaluable lesion per RECIST criteria 6. adequate marrow, hepatic, renal and cardiac functions 7. One prior treatment of cytotoxic chemotherapy (including adjuvant treatment within 12 months) 8. provision of a signed written informed consent 1. severe comorbid illness and/or active infections 2. pregnant or lactating women 3. active CNS metastases not controllable with radiotherapy or corticosteroids 4. known history of hypersensitivity to study drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>advanced biliary tract carcinoma</keyword>
	<keyword>Sunitinib</keyword>
</DOC>